Evidence map›Paper›PMID 35487999›Full record

ArticleAAPS PharmSciTech2022

Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance.

Maomao Tang, Yuzhe Huang, Xiao Liang, Yaotian Tao, Ning He, Zhenbao Li, Jian Guo, Shuangying Gui

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. siRNA-loaded folic acid-modified TPGS alleviate MASHInternational journal of biological sciences · 2024
    Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Maomao Tang *Department of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China.
Yuzhe Huang *Department of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China.
Xiao LiangDepartment of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China.
Yaotian TaoDepartment of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China.
Ning HeDepartment of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China.
Zhenbao LiDepartment of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China.
Jian GuoDepartment of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China. guoj0719@123.com.
Shuangying GuiDepartment of Pharmacy, Anhui University of Chinese Medicine, No. 350, Longzihu Road, Hefei, Anhui, 230012, People's Republic of China. guishy0520@126.com.
Anhui University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) is a key determinant for hepatocellular carcinoma chemotherapy failure. P-glycoprotein is one of the main causes of MDR by causing drug efflux in tumor cells. In order to solve this thorny problem, we prepared a sorafenib-loaded polylactic acid-glycolic acid (PLGA) - D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (SPTNs). SPTNs were successfully synthesized through an ultrasonic emulsion solvent evaporation method with a favourable encapsulation efficiency of 90.35%. SPTNs were almost spherical in shape with uniform particle size (215.70 ± 0.36 nm), narrow polydispersity index (0.27 ± 0.02) and negative surface charge (-26.01 ± 0.65 mV). In the cellular uptake assay, the intracellular coumarin-6 (C6) fluorescence of TPGS component-based PLGA nanoparticles (C6-PTNs) was 1.63-fold higher relative to that of PVA component-based PLGA nanoparticles (C6-PVNs). The half-maximal inhibitory concentration and apoptosis ratio of SPTNs against HepG2/MDR cells were 3.90 μM and 75.62%, respectively, which were notably higher than free SF and sorafenib-PLGA-PVA nanoparticles (SPVNs). The anti-drug efflux activities of SPTNs were assessed by the intracellular trafficking assay using verapamil as a P-gp inhibitor. SPTNs could effectively inhibit the drug efflux in tumor cells detected by flow cytometry, and suppressed relative MDR1 gene as well as P-glycoprotein expression in tumor cells. Attributed to the MDR reversion effect of SPTNs, the in vivo antitumor efficacy experiment showed that SPTNs significantly inhibited the tumor growth of HepG2/MDR xenograft-bearing nude mice, and obviously reduced the toxicity against liver and kidney compared with SF treatment. In summary, SPTNs, as highly efficient and safe antitumor nano delivery systems, showed promising potential for hepatocellular carcinoma therapy through reversing P-glycoprotein-mediated MDR. Graphical Abstract.

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsalpha-TocopherolAnimalsATP Binding Cassette Transporter, Subfamily BDrug Resistance, MultipleGlycolatesHumansLactic AcidMiceMice, NudePolyestersPolyethylene GlycolsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSorafenibalpha-TocopherolATP Binding Cassette Transporter, Subfamily BGlycolatesglycolic acidLactic AcidPolyesterspolyethylene glycol 1000Polyethylene GlycolsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymerpoly(lactide)SorafenibtocophersolanVitamin Ehepatocellular carcinomamultidrug resistancePLGAsorafenibTPGS

Identifiers

PMID35487999
OpenAlexW4225123732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.